AUNA Q1 Call: Mexico Recovery Still Pending, Covenant Headroom Remains Tight

What happened

Q1 2026 earnings call reiterated FY26 guidance of ~10-14% FX-neutral revenue and EBITDA growth, but Mexico KPIs remained weak with utilization flat YoY and emergency visits declining 2.3%. Management cited preferred-provider tier status and ISSSTELEON repricing as levers for H2 recovery, but the lack of near-term inflection keeps the burden of proof on 2Q/3Q26 KPI prints. Covenant headroom stayed narrow with leverage at 3.64x vs 3.90x limit and interest coverage at 1.81x just above the 1.75x floor, leaving no room for operating missteps. Peru and Colombia segments performed well with improving utilization, partially offsetting Mexico's drag, but Mexico's 23% of revenue and 27% of EBITDA means it remains the swing factor. No new capital structure actions were announced, and management emphasized deleveraging, but the balance sheet flexibility remains constrained by annual revolver renewals and tightening covenant steps in 2H26.

Implication

The Q1 call reaffirmed the thesis that AUNA's near-term return hinges on a Mexico volume inflection in 2Q/3Q26. Without clear KPI improvement, the equity remains a highly levered play on operating execution with limited downside protection. Long-term investors should wait for confirmatory data before adding positions, as leverage and coverage requirements become stricter in 2027.

Thesis delta

The master report's wait rating is unchanged. The Q1 call provided no evidence that Mexico patient volumes are recovering faster than the FY25 trend. The confidence in the base case remains conditional on H2 2026 data; the path to bull case requires emergency visits to reverse YoY declines in 2Q26.